The global colorectal cancer therapeutics market size is expected to reach USD 16.7 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 4.7% from 2023 to 2030. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.
Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma’s cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon’s Napabucasin is a cancer stem cell inhibitor targeting STAT-3.
There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.
Upcoming patent expiries of key products such as Roche’s Avastin, Amgen’s Vectibix, and Sanofi’s Zaltrap will lead to biosimilar penetration. Amgen/Allergan’s Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.
Colorectal Cancer Therapeutics Market Report Highlights
- Immunotherapy dominated the market based on drug class in 2022, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
- Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
- S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
- Roche led the colorectal cancer industrial setting in 2022 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2022. However, Roche is projected to lose market share on grounds of Avastin’s patent expiry and biosimilar penetration
- Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.
Get Sample Copy of Colorectal Cancer Therapeutics Market
Colorectal Cancer Therapeutics Market Segmentation
Grand View Research has segmented the global colorectal cancer therapeutics market based on drug class and country:
Colorectal Cancer Therapeutics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Chemotherapy
- Immunotherapy
- Others
Colorectal Cancer Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Key Players of Colorectal Cancer Therapeutics Market
- Amgen, Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Lilly
- Merck & co., Inc.
- Hoffmann-La Roche Ltd.
- Sanofi
Order a free sample PDF of the Colorectal Cancer Therapeutics Market Intelligence Study, published by Grand View Research.
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian